Hormonal research peptides

These compounds are grouped because researchers study how they interact with pathways involved in hormone release. Their targets and molecular forms differ. Inclusion in this category is not a claim that the supplied vial balances hormones, treats a condition or improves any function.

The distinction between the two CJC products is especially important: a paper describing long-acting CJC-1295 cannot automatically support statements about material sold as CJC-1295 no DAC.

What the studies look at

Growth hormone, usually shortened to GH, is released by the pituitary gland. Researchers can examine this release in cultured pituitary cells or measure hormone concentrations in animal models. They also investigate receptor activity, peptide breakdown and how long a tested compound remains detectable.

These are separate measurements. Detecting a peptide in blood does not establish a particular hormone-release pattern, and measuring GH release does not demonstrate a clinical outcome.

Ipamorelin

Ipamorelin is a synthetic peptide made from five amino-acid building blocks. It is studied as a growth-hormone secretagogue, meaning a compound that stimulates GH release in the experimental system. Its receptor pathway differs from the GHRH-receptor pathway associated with the CJC compounds.

Raun and colleagues examined ipamorelin in cultured rat pituitary cells, rats and pigs. They measured GH release and compared responses involving other hormones. The reported selectivity belongs to those test conditions; it should not become a blanket claim that ipamorelin affects no other hormones. These were cell and animal findings, not results in people or tests of an EU Peptides vial.

CJC-1295 no DAC

The material commonly sold as CJC-1295 no DAC is also called modified GRF 1-29. It is a modified, 29-amino-acid analogue of growth-hormone-releasing hormone, or GHRH. An analogue is a molecule designed to resemble another molecule while incorporating structural changes.

The EU Peptides product description identifies the no-DAC material as modified GRF 1-29. It lacks the albumin-binding attachment used in the long-acting CJC-1295 design. Consequently, findings about that attachment, albumin binding or prolonged circulation must not be presented as findings for the no-DAC product.

CJC-1295 with DAC

DAC stands for Drug Affinity Complex. In this design, an attached chemical group enables the peptide to bind to albumin, a protein present in blood. Researchers investigate how this changes the compound’s persistence while retaining activity at the GHRH receptor.

Jetté and colleagues examined albumin-linked GHRH analogues in cultured rat pituitary cells and rats. Their work identified CJC-1295 as an active, longer-lasting analogue and investigated its association with circulating albumin. This was preclinical research involving the DAC-containing design. It did not test modified GRF 1-29 sold without DAC, or any EU Peptides batch.

Compare the three compounds

The catalogue also includes a CJC-1295 + Ipamorelin blend. That is a separate mixed product. Its documentation must identify the CJC form and both component amounts. A blend is not a new mechanism, and papers on the individual peptides do not establish the behaviour of the finished mixture.

For any CJC comparison, match the complete chemical identity before comparing results. “CJC-1295” without a DAC designation leaves a material distinction unresolved. The vial label, product description and eventual certificate should describe the same substance.

Certificate and lot

Batch certificates are not yet available, so no batch-specific purity result is stated here.

A batch will be listed for sale only after its certificate has been checked. The lot number on the file must match the lot number on the vial. If either number is missing or the numbers differ, that batch is not listed. A certificate for CJC-1295 with DAC cannot document the no-DAC form.

The acceptance requirement is at least 99% purity by HPLC. This is the listing threshold, not an established result for uncertified material. The published figure must be the figure on that batch’s certificate.

HPLC assesses purity by separating components under the stated method. Where the certificate includes mass spectrometry, that result is also reviewed for evidence supporting identity. Neither test establishes GH release, hormone selectivity or a clinical effect.